FUTURE OF CANCER CARE TODAY
We help patients and caregivers explore beyond standard of care.
What is possible in cancer care outpaces what most patients access.
Many patients are not aware of the full range of diagnostic and therapeutic options for their cancer. Some have been available for years. Others are at the leading edge.
Drugs already approved for your cancer or related cancers. Expanded gene panels, beyond what your treating team may have ordered. Second opinions at major academic centers.
Clinical trials, single-patient INDs, expanded access programs. Open-minded physicians willing to operate beyond standard protocols. Tumor-informed ctDNA and other specialized monitoring.
Personalized therapeutics (mRNA vaccines, antibody-drug conjugates, cell therapies, targeted radioligands). Patient-initiated research collaborations. Advanced single-cell and functional analysis.
From self-serve reading to more sustained support.
FCCT is not a medical concierge. We map options non-exclusively, don't coordinate care, and are open source. Most families start with the public resources; some need direct case help. Our body of work grows over time as we learn what families need.
Read at your own pace, share with your treating team. Open access, continuously expanding.
- Playbooks: finding open-minded physicians, building tumor boards, structuring treatment ladders, navigating trials and expanded access.
- Suppliers and care providers: who delivers what, at what cost, with what evidence.
Reach out with a focused question on a specific resource, finding, or decision.
For families navigating active complex decisions.
- Research synthesis: reading molecular reports across platforms, surfacing options for the treating team, finding trials and access pathways.
- Resource awareness: suppliers, physicians, research groups, and support services when there's a likely fit.
A connective layer for clinicians, suppliers, and researchers.
FCCT is an open layer between families and those advancing cancer care: the clinicians who take complex cases, the suppliers running specialized diagnostics and therapeutics, the research groups open to outside samples. Much of this work exists but is hard to find. Companies and programs are listed openly, never asked for exclusivity, and the content is open source for anyone to build on.
Regulatory reform could open faster paths to experimental access, GMP-light production, and parallel treatments. FCCT is committed to working with regulators and policymakers to advance these directions on behalf of patients. Data sharing could give patients real control over their records and tissue across institutions.
Building the open, public layer.
Elements of personalized cancer care exist today: advanced diagnostics, emerging therapeutics, monitoring tools, n-of-one physicians, research groups open to outside samples. They are scattered across hundreds of suppliers and institutions. Most families never see them.
FCCT is building the open source, public layer that connects what's possible to the family in the middle: playbooks for the decisions families face, a reference for the companies and programs who can act, and case help when families need it.
Help cancer patients and families see and act on the full range of options that exist beyond standard of care.
Personalized, advanced cancer care, accessible to every patient who seeks it.
When Sid Sijbrandij (founder of GitLab) faced a recurrence of his rare bone cancer after standard of care was exhausted, he assembled a team and pursued a more intensive approach: running every available diagnostic, pursuing personalized treatments and multiple strategies in parallel, and measuring what was working in real time. The results were striking, including significant tumor response that enabled surgical removal.
Sid's story is one data point. What worked for him may not work for every patient, and we are still learning what generalizes. Future of Cancer Care Today, incubated by Sid's foundation, aspires to make the path beyond standard of care reachable for more families.
We would welcome a conversation.
If our work could be useful to you or your community, please reach out. There is no cost to patients or families for our help.
If you are facing complexity in your care.
Whether you are newly diagnosed, facing progression, or trying to figure out what comes next, we may be able to help you think more clearly about the path ahead.
If your work could complement ours.
If you are working in diagnostics, therapeutics, personalized medicine, or health technology, and believe patients need better support navigating complexity, let's talk about how our work could complement yours.
A note on our role.
Future of Cancer Care Today is not a medical provider. We do not diagnose, prescribe, or direct treatment. We provide a non-clinical support layer focused on information, education, and decision support, intended to complement your relationship with your care team. Some materials may be generated with the support of artificial intelligence and should be reviewed with your medical providers before informing any care decisions. All decisions regarding your care belong to you and your doctor.
SELF-SERVE PLAYBOOKS
updated regularly
SUPPLIERS AND CARE PROVIDERS
updated regularly
A curated list of resources we have come across in our work: providers of specialized diagnostics and therapeutics, clinicians who take complex cases, and research groups open to outside samples. Access ranges from available today through your oncology team, to reachable through specific eligibility or clinical trials. Use as a reference for conversations with your care team, not as medical advice.
-
Services that preserve a patient's tumor tissue at biopsy or surgery for future testing, including therapies that may not yet exist at the time of collection.
SpeciCare (US). Patient-orderable.
StoreMyTumor (US, Europe). Patient-orderable.
Kernis Health (US). Patient-orderable. Even One Ventures company.
-
Tests that examine the molecular makeup of a tumor to identify treatment targets and biomarkers. Usually performed on a biopsy or surgical sample.
Tempus (US). Physician-ordered.
Caris Life Sciences (US). Physician-ordered.
Foundation Medicine (US). Physician-ordered.
Boston Gene (US). Also includes immune microenvironment analysis. Physician-ordered.
Noetik (US). Whole-exome sequencing, spatial profiling, and IHC with raw data returned to the patient. Patient-orderable.
Valius Sciences (US). Maximalist diagnostics adding single-cell and proteomic profiling. Patient-orderable. Even One Ventures company.
BC Cancer Personalized Oncogenomics Program (Canada). Referral pathway in Canada.
CeGaT (Germany). Tumor-normal comparison with patient-specific neoantigen identification. Physician-ordered.
OncoDNA (Belgium). Physician-ordered.
Hartwig Medical Foundation (Netherlands). Referral through participating Dutch hospitals.
-
Blood-based tests that detect tumor DNA fragments to monitor disease over time, including residual disease after surgery, early recurrence, and treatment response.
BillionToOne (US). Physician-ordered.
Guardant (US). Physician-ordered.
Natera (US). Physician-ordered.
Personalis (US). Physician-ordered.
-
Specialized cancer imaging and radioligand therapies that target tumor-specific markers. Theranostics pairs imaging and treatment using the same molecular target, for example PSMA in prostate cancer or somatostatin receptors in neuroendocrine tumors.
New York Proton Center (US). Proton-beam radiation therapy for solid tumors. Patient-bookable through oncology referral.
Excel Diagnostics and Nuclear Oncology Center (US). Patient-bookable through oncology referral.
Johns Hopkins Theranostics Center (US). Referral through oncology consult.
Princess Margaret Cancer Centre Theranostics (Canada). Referral pathway in Canada.
Curanosticum Wiesbaden-Frankfurt (Germany). Led by Dr. Richard Baum, with FAPI PET and investigational radioligand therapies. Patient-bookable through oncology referral.
University Hospital Essen Nuclear Medicine (Germany). Patient-bookable through oncology referral.
Royal Marsden Theranostic Centre (UK). Referral pathway in UK.
-
Tests that grow a patient's tumor cells in the lab and screen them against multiple cancer drugs to predict which may work best, beyond standard of care.
Travera (US). Live-cell screening including immunotherapies. Physician-ordered.
Kiyatec (US). Ex vivo 3D drug response testing focused on ovarian, breast, glioblastoma, and rare tumors. Physician-ordered.
HUB Organoids (Netherlands). Through partner hospitals.
2cureX (Denmark). Through hospitals in Denmark, Germany, Sweden, and the UK. Physician-ordered.
-
Tests that characterize a patient's immune response to their tumor, including which immune cells are present, what targets they recognize, and how active they are. Useful for guiding immunotherapy decisions.
Personalis (US). Combines tumor sequencing with neoantigen prediction, TCR repertoire, and immune cell composition. Physician-ordered.
Adaptive Biotechnologies (US). FDA-cleared minimal residual disease assay for B-cell malignancies (multiple myeloma, ALL, CLL, DLBCL). Physician-ordered.
Arden Bio (US). Adds biology-matched immune therapy recommendations alongside tumor microenvironment profiling. Patient-orderable. Even One Ventures company.
Veracyte (France). Quantifies intratumoral T-cell density in colon cancer. Physician-ordered.
-
Therapies that train the immune system to recognize and attack tumor-specific proteins. Most cancer vaccines today are only accessible through clinical trial enrollment. The exceptions are largely on the peptide side: a handful of clinics and programs can deliver personalized peptide vaccines to patients who do not qualify for trials, while personalized mRNA vaccines remain almost entirely confined to sponsor-run trials. Practically, this means a peptide vaccine is more obtainable today.
Jaime Leandro Foundation (US). Personalized peptide vaccines through FDA Expanded Access (compassionate use) when no trial is available. Patient-orderable.
Areca Bio (US). Modality-agnostic neoantigen design (peptide, DNA, mRNA). Patient-orderable.
CeCurio (Germany). Personalized peptide vaccines through CeGaT collaboration, with real-world survival data in glioblastoma. Patient-bookable in Germany.
Moderna (US). Personalized mRNA neoantigen vaccines. Trial enrollment.
Houston Methodist Center for RNA Therapeutics (US). Academic mRNA vaccine program led by Dr. John Cooke. Trial enrollment as studies open.
BioNTech (Germany). Personalized mRNA neoantigen vaccines. Trial enrollment.
IO Biotech (Denmark). Off-the-shelf peptide vaccine targeting IDO and PD-L1. Trial enrollment.
Echo (US). Personalized mRNA vaccines designed and manufactured for individual patients. Patient-orderable. Even One Ventures company.
-
Therapies that use engineered immune cells (CAR-T, TCR-T), tumor-infiltrating lymphocytes (TIL), or antibodies to target cancer. Most are accessed through clinical trial enrollment; FDA-approved exceptions noted below.
Iovance (US). First FDA-approved TIL therapy for advanced melanoma, with several others in trials. Available at authorized treatment centers in the US.
UCSF Cancer Immunotherapy Program (US). Standard-of-care CAR-T for B-cell blood cancers and multiple myeloma; trials in solid tumors. Referral through oncology consult.
Stanford Center for Cancer Cell Therapy (US). Standard-of-care CAR-T for B-cell lymphoma; trials in melanoma, solid tumors, and inoperable brainstem gliomas, including pediatric DIPG. Referral through oncology consult.
Memorial Sloan Kettering Cellular Therapeutics Center (US). Standard-of-care CAR-T for blood cancers and trials in solid tumors. Referral through oncology consult.
Immatics (Germany). Engineered TCR-T targeting PRAME, expressed across many solid tumors. Trial enrollment.
DKFZ Heidelberg (Germany). Heidelberg cellular therapy hub running TCR-T, CAR-T, and bispecifics with on-site GMP cleanrooms. Dirk Jäger group; referral pathway in Germany.
Ranata Therapeutics (US). Anti-idiotype antibodies and bispecifics for clonal B and T cell elimination in cancer and autoimmune disease. Patient-orderable. Even One Ventures company.
-
Engineered viruses that selectively infect and destroy tumor cells while triggering an immune response. Access is currently via clinical trial enrollment.
Replimune (US, UK). Engineered HSV-1 oncolytic virus with BLA under FDA review for advanced melanoma; broader pipeline includes liver and other solid tumors. Trial enrollment in the meantime.
Candel Therapeutics (US). Adenoviral oncolytic combined with valacyclovir, with trials in prostate cancer, pancreatic cancer, and NSCLC. Trial enrollment.
-
Services that help patients and physicians identify relevant open clinical trials. Most use AI-driven matching against medical records or symptom profiles.
Picnic Health (US). Patient-accessible.
Massive Bio (US). Patient-accessible.
Antidote (US, UK). Patient-accessible.
ClinicalTrials.gov (US). Official US government registry of clinical trials worldwide; the underlying data source most matching tools draw from. Patient-accessible.
Klineo (France). European trial coverage. Patient-accessible.
EU Clinical Trials Information System (CTIS) (EU). Official European Medicines Agency database of clinical trials in EU member states. Patient-accessible.
-
Patient navigation services, AI-driven tools, and care coordination resources to help patients and families understand their disease, find treatment options, and manage care over time.
Cancer Commons (US). PhD-led navigation plus an N-of-1 site-less observational study matching off-guideline FDA-approved drugs through the patient's own oncologist. Patient-accessible.
OpenCancerAI (US). Open cancer infrastructure and AI to reduce information asymmetry for patients. Patient-accessible.
Pathfinder Oncology (US). High-touch personalized treatment-pathway concierge service for advanced cancer. Patient-accessible.
Private Health Management (US). High-touch patient guidance, specialist access, second opinions, and care coordination. Patient-accessible.
CareCircles.ai (US). Patient-controlled support hub coordinating help, updates, and burden during treatment, with AI companion. Patient-accessible.
-
Physicians and centers known for taking complex cases, considering off-guideline options, and supporting patients exploring beyond standard of care.
Asthra Health (US). Outside clinical opinion for complex cancer cases. Patient-bookable.
Sarcoma Oncology Center (US). Sarcoma-focused second opinions, clinical trials, and multimodal treatment planning. Patient-bookable.
Private Medical (US). Private Medical takes complex cases with attention to overlooked clinical angles. Patient-bookable.
Gustave Roussy (France). Europe's largest comprehensive cancer center, with a strong precision oncology program, large Phase I trials portfolio, and international referral pathway. Referral pathway in France.
Poornima Parameswaran, Ph.D.
Poornima is a scientist and entrepreneur whose work has focused on bridging the gap between scientific discovery and real-world impact. At Stanford University, she developed technology that increased scale and cut DNA sequencing costs by 50x, and taught the first course on the applications of genomics. She cofounded a genomics and AI company when her twins were one year old and led it from inception through acquisition. She was also diagnosed with multiple myeloma, which gave her a perspective on the healthcare system that no amount of scientific training could, and taught her firsthand what it takes to advocate for your own care when the system is not built to help you do that. Her work spans both for-profit and non-profit sectors; today she chairs the Strategy and Innovation Committee of the International Myeloma Foundation. She draws on her experiences as a scientist, entrepreneur, diagnosed patient, and parent, to inform and guide this work.
LinkedIn Profile →
Bayli DiVita Dean, Ph.D.
Bayli is a scientist and science communicator dedicated to improving the lives of those diagnosed with cancer. She developed her expertise in cancer immunotherapy research at the University of Florida and in translating complex scientific findings into accessible language during her time at the American Brain Tumor Association. Bayli was also a fellow at the National Institutes of Health, Office of the Director, through the American Association for the Advancement of Science Science and Technology Policy Fellowship, where she addressed policy needs related to incorporating the public into clinical research and bioethical issues. Inspired by her mother’s diagnosis with metastatic colon cancer, she now applies her caregiving, scientific, and communication expertise to provide information and compassion to clients of FCCT.
LinkedIn Profile →
Future of Cancer Care Today is incubated by the Sijbrandij Foundation.